Given the heterogeneous nature of cancer and the variability in responses to immunotherapy, elucidating the role of PLEK2 across multiple tumor types could aid in the identification of novel therapeutic targets and improve the precision of immunotherapy. This evidence concerns the gene PLEK2 and neoplasm.